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Aptamers are small, single-stranded oligonucleotides (DNA or RNA) that bind to their target with high specificity and
affinity. Although aptamers are analogous to antibodies for a wide range of target recognition and variety of
applications, they have significant advantages over antibodies. Since aptamers have recently emerged as a class of
biomolecules with an application in a wide array of fields, we need to summarize the latest developments herein. In
this review we will discuss about the latest developments in using aptamers in diagnostics, drug delivery and imaging.
We begin with diagnostics, discussing the application of aptamers for the detection of infective agents itself, antigens/
toxins (bacteria), biomarkers (cancer), or a combination. The ease of conjugation and labelling of aptamers makes
them a potential tool for diagnostics. Also, due to the reduced off-target effects of aptamers, their use as a potential
drug delivery tool is emerging rapidly. Hence, we discuss their use in targeted delivery in conjugation with siRNAs,
nanoparticles, liposomes, drugs and antibodies. Finally, we discuss about the conjugation strategies applicable for
RNA and DNA aptamers for imaging. Their stability and self-assembly after heating makes them superior over
protein-based binding molecules in terms of labelling and conjugation strategies.
[Chandola C, Kalme S, Casteleijn MG, Urtti A and Neerathilingam M 2016 Application of aptamers in diagnostics, drug-delivery and imaging.
J. Biosci. 535–561]
1. Introduction
Aptamers are small, single-stranded oligonucleotides
(DNA or RNA), which specifically bind to their target with
high affinity. The term ‘aptamers’ comes from the Latin
word aptus (fitting) and the Greek word meros (part). The
DNA and RNA aptamers can bind to the same target with
different folding patterns and sequences. Aptamers are se-
lected from a pool of a random oligonucleotide library
(>1015 random oligonucleotides) by iterative rounds of
affinity purification and amplification by a process called
Systematic Evolution of Ligands by Exponential enrich-
ment (SELEX) (figure 1). This concept of nucleic acid
binding to their targets like a protein came into the light
when small RNA structures were found to bind with viral or
cellular proteins at high affinity and specificity during an
investigation on human immunodeficiency virus (HIV) and
adenovirus (Song et al. 2012). Initial studies on aptamers
started with the report of SELEX method in 1990 by both
Gold’s and Szostak’s groups, which was more than two
decades ago (Ellington and Szostak 1990; Tuerk and Gold
1990). SELEX is a basic technique for the selection of
aptamers in vitro against various targets, from small bio-
molecules to larger biomolecules like proteins and even
cells. The interaction between an aptamer and its target
involves different intermolecular interactions including
van der Waal’s forces, electrostatic interactions between
charged groups, three-dimensional shape, stacking and hy-
drogen bonds. Aptamers can fold into a variety of second-
ary and tertiary structural elements, like stem loops,
pseudoknots, kinks, and bulges, which can recognize mul-
tiple surfaces as target binding sites. Due to the ability of
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aptamers to recognize targets and binding specificity, they
are often compared to antibodies. However, unlike anti-
bodies, aptamers can be selected under non-physiological
conditions like extremely high or low temperature, or pHs.
Aptamers can be readily chemically synthesized with min-
imal batch-to-batch variations. Moreover, they are easily
selected, more stable to heat and withstand organic sol-
vents, and show low immunogenicity. Compared to anti-
bodies, the smaller size of aptamers makes them easier to be
synthesized in large quantities, and can be easily introduced
with a wide range of chemical modifications, which help
them to retain their binding and inhibitory behavior after
immobilization on a carrier material or after delivery into
animals. They are 1/10th the molecular weight of antibodies
and yet provide complex folded tertiary structures with
sufficient recognition surface areas to rival and even sur-
pass antibodies. All these properties provide a potential
market for aptamers in the field of biomedical applications.
Aptamers have been studied as a biomaterial for numer-
ous applications like diagnostics and in the development of
new drugs, drug delivery systems and imaging. Today at
least a dozen distinct aptamer products are being tested in
several dozen trials. The first aptamer approved by Food and
Drug Administration (FDA) for use in humans is Pfizer's
Macugen that is administered locally to treat age related
macular degeneration (AMD) by targeting vascular endothe-
lial growth factor (VEGF) (Ruckman et al. 1998); however,
monoclonal antibodies that are more effective clinically for
this purpose have been developed (Fong and Lai 2013). The
most advanced aptamer in cancer setting is AS1411, a 26-
mer guanosine rich oligonucleotide against human tumor,
formerly known as Agro100 (Teng et al. 2007). In the recent
years, the aptamer technology field has evolved significant-
ly, and is regarded as a more effective technology as the
number of studies in the application of aptamers is rapidly
increasing.
In this article we emphasize on applications of aptamer
in the field of (a) diagnostics, (b) drug delivery and (c)
imaging. This era is steering towards translational research
where there is a need to move the research findings from
bench-to-bedside, i.e., for clinical outcomes with commer-
cial viability. Aptamers, because of their wide variety of
Figure 1. Diagrammatic representation of systematic evolution of ligands with exponantial enrichment (SELEX).
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applications and the ability to undergo easy modifications
are a good example to be exploited. Diagnostics, drug
delivery and imaging are gaining attraction in the field of
translational research because of their huge impact towards
diagnosing and treating a disease. Hence, in this review
article we have focused on the latest developments in the
application of aptamers and how it has affected the above
mentioned three fields, describing the advantages and the
challenges ahead.
We begin with the role of aptamers in diagnostics where
they have been a tradition in this application. As known,
signal generated by a conformational change induced by the
presence of a ligand is ideal for the creation of sensors for
which aptamers are ideal candidates. The ease of conjugation
and labelling of aptamers allows them to be combined with
other advanced technologies like flow cytometry, microflui-
dic cell separation, endogenous nucleic acid analysis, nano-
particle based sensing and, thus, positioning them as a
potential tool for diagnostics. We will cover the application
of aptamers for detection of pathogenesis involving, bacteria,
bacterial toxins, viruses, parasites and cancer. Then we will
move towards the application of aptamers as drug delivery
agents. Off-target delivery of drugs during therapeutic treat-
ment of various diseases, especially in chemotherapy for
cancer, is an important problem to be overcome. Here, we
have discussed that how aptamers, due to their small size and
high specificity, have been used for targeted drug delivery.
They are either bound with drugs alone, or used in conjuga-
tion with nanoparticles, liposomes and antibodies for in-
creased delivery of various therapeutic payloads. Finally,
we shed light on the role of aptamers in imaging where they
have been utilized in clinical and molecular imaging. We
discussed how aptamers have been used in positron emission
tomography (PET) scans, magnetic resonance imaging
(MRI), CT, ultrasound and nuclear imaging. Also, we briefly
discuss about the conjugation strategies of fluorescent
probes with aptamers.
2. Aptamers in diagnostics
Key for the effective treatment of any disease is an early and
accurate diagnosis. Early diagnosis is only possible with
sensitive methods involving acute detecting agents such as
aptamers. Aptamers have been used for the detection of
bacterial, parasital and viral mediated diseases along with
cancer (figure 2). In the field of diagnostics, aptamers are
applied for the detection of infective agents itself, the detec-
tion of the antigens/toxins (bacteria), or biomarkers (cancer),
or a combination. Some existing diagnostic methods are in
need of high-end machinery and skilled people, which
increases the cost. Currently used methods in diagnosis
may take long due to the isolation of infective agents and
subsequent cultivation for detection. Also, in some cases
enrichment of causative agents is required for proper diag-
nosis because of its low titer. In order to address these points
and simplify the process, aptamers can be used. In the
following sections we discuss the use of aptamers as a
diagnostic tool for detection of various diseases including
cancer and other diseases caused by bacteria, parasites and
viruses.
2.1 Bacteria
Increasing bacterial infections have triggered an unmet de-
mand for the development of rapid and sensitive point of
care diagnostic tests. In case of Staphylococcus aureus,
infection-detection combined with culturing takes days
while other methods are less cost effective. A new ultra-
sensitive and non-polymerase chain reaction (PCR)-based
method has been developed which measures the resonance
light-scattering signal of aptamer-conjugated gold nanopar-
ticles to detect a single cell of S. aureus cell within 1.5 h
(Chang et al. 2013). A sandwich luminescent bioassay was
developed for the detection of Salmonella typhimurium and
S. aureus simultaneously using an aptasensor with magnetic
nanoparticles (MNPs). In this bioassay two different
aptamers were used, and both were immobilized on magnetic
nanoparticles to capture the bacteria; furthermore, these two
aptamers were modified with nanoparticles making them
dual color labels, and allowed to bind the captured bacteria.
The luminescent signal generated by this assay showed a
linear correlation with S. typhimurium and S. aureus con-
centrations. Detection limits for this method was found to be
5 and 8 cfu/ mL for S. typhimurium and S. aureus, respec-
tively. This assay is highly sensitive and selective for these
two different types of bacteria (Duan et al. 2012). Zelada-
Guillén and coworkers reported label free detection of
S. aureus in real-time. A biosensor was fabricated with
aptamers against S. aureus and single-walled carbon nano-
tubes (SWCNTs) acting as potentiometric transducers. The
aptamers were attached to SWCNTs in two ways: (i) drop-
casted pyrenil modified aptamers were non-covalent
adsorbed to the external walls of the SWCNTs, and (ii)
amine-modified aptamers were covalently bound to carbox-
ylic groups at the ends of the SWCNTs which were intro-
duced by oxidation. Both approaches indicated a linear
correlation between potential, as a function of decade, and
bacteria concentration. This biosensor was tested on pig skin
as a substitute for human skin (Zelada-Guillén et al. 2012).
Recently the dos Santos team used previously screened
aptamers for S. aureus to evaluate its use in diagnostics by
scintigraphy. The aptamers were directly radiolabeled with
technetium-99m (99mTc) and injected in three groups of
Swiss mice. The first two groups were infected with
S. aureus and C. albicans individually, whereas the third
group was induced for aseptic inflammation. Aptamers were
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able to detect infection foci caused by S. aureus and
C. albicans with a target/non-target ratio of 4.0±0.5 and
2.0±0.4, respectively. The ratio for aseptic inflammations
was 1.2±0.2. These results show the potential of 99mTc
labeled aptamers for the diagnosis of bacterial infections by
scintigraphy (dos Santos et al. 2015). Another report states
development of sensor based on graphene bound to inter-
digital gold electrodes (IDE) connected to a series of elec-
trode piezoelectric quartz crystals (SPQC) for the specific
detection of S. aureus. S. aureus aptamers were connected to
graphene via π–π stacking of DNA bases. The aptamers fall
from the graphene surface in the presence of S. aureus
resulting in a change in the electric parameters and altering
the oscillator frequency of the SPQC. This sensor can detect
S. aureus rapidly and specifically within 60 min and can be
used for clinical diagnosis (Lian et al. 2015).
Along with early detection of a disease, it is also impor-
tant to find the causative agent of the disease which helps in
deciding the correct treatment plan. Here, one bottleneck is
the detection limit, which is sometimes below the level of the
infection dose required by the pathogen to onset a disease or
because the diagnostic method is not adept to detect low
levels of pathogens. Salmonellosis is one of the major food
borne diseases caused by Salmonella enterica serovar typhi-
murium. Enrichment of S. typhimurium cells in the sample is
important, which can be carried out by concentrating
S. typhimurium using specific aptamers, followed by direct
detection using qPCR. Similarly, DNA and RNA aptamers
were selected against several species of Salmonella with
varying dissociation constants (table 1).
Escherichia coli (E. coli) O157:H7 is an enterohemorrha-
gic E. coli strain, which secretes exotoxins known as
Figure 2. Application of aptamers in field of diagnosis.
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verotoxins (shiga like toxins). Currently available detection
methods for this strain are time consuming as very low dose
of infection causes the disease and pathogen numbers have
to be increased to reach the detection level. A subtractive
cell-SELEX method was employed by Lee et al. (2012) for
selective and specific aptamer detection of E. coli O157:H7
related to food borne diseases. In this method the RNA
aptamer library was allowed to bind with E. coli K12, and
unbound aptamer library was further used for the selection
against E. coli O157:H7. The specificity of the aptamers was
tested using aptamer-immobilized ELISA, real-time PCR
analysis, and an aptamer-linked precipitation test. These tests
revealed the specificity of aptamers towards lipopolysaccha-
ride O antigen on O157:H7. Therefore, authors suggest its
application as a diagnostic ligand for the detection of E. coli
O157:H7 (Lee et al. 2012). When cell SELEX is used, most
of the time it is not possible to recognize the target for the
selected aptamers simply because the targets for different
aptamers on the cell surface could be the same or different.
Thus many aptamers can be selected towards a cell with high
affinity and specificity. Taking advantage of this effect by
combining aptamers against same bacteria to increase the
sensitivity, Kim et al. (2014) screened aptamers against
E. coli using cell SELEX and compared the sensitivity of
biosensors with a single aptamer and a cocktail of aptamers.
A mixture of fluorescence-tagged aptamers showed an en-
hanced signal compared to the single aptamer. This was
further evaluated by immobilizing the single aptamer and
the mixture of aptamers on gold electrodes resulting in a
detection limit of approximately 18 times more than that of
the single aptamer. This strategy was also suggested for the
detection of other bacteria, cancer cells, and tissues (Kim
et al. 2014).
Burkholderia pseudomallei is a causative agent of melioi-
dosis. The symptoms may include pain in chest, bones/
joints, cough, skin infections, lung nodules and pneumonia
which are noticed after high exposure to the bacteria. Lack of
intensive antimicrobial treatment for a prolonged period may
cause death. Hence, the need of an improved diagnostic
reagent is vital for early detection. For this purpose, high
affinity aptamers were selected against recombinantly
expressed B. pseudomallei specific proteins: a putative oxi-
doreductase BPSL2748 and secretion pathway proteins
(BipD and BopE type III), which are considered to be
potential targets for applications in diagnostic assays for
B. pseudomalle (Gnanam et al. 2008).
Bacterial toxins are major components of virulence fac-
tors of pathogenic bacteria and thus detecting them is an
imperative for the diagnosis of a bacterial disease. For ex-
ample, toxin A (TOA) is one of the lethal enterotoxins
produced by Clostridium difficile and causes antibiotic-
associated diarrhea and pseudomembranous colitis in
humans. Presently available laboratory tests for the diagnosis
of C. difficile infection are by detecting bacteria itself and
TOA or Toxin B (TOB is another potent cytotoxin of
C. difficile) in stool samples. However, the microbiological
culture method is insensitive and time consuming, the cyto-
toxic assay is costly and requires expertise. Additionally, an
enzyme immunoassay can give false positive results due to
cross-reacting antibodies, and polymerase chain reaction
(PCR)-based tests requires pre-treatment of sample, where
small amounts of free DNA can affect the results. Here,
aptamer biosensors for the detection of TOA in clinical
samples provide a better alternative. Luo et al. (2014) devel-
oped a biosensor based on the conformational change of an
aptamer for quantitative analysis of TOA in stool samples.
This biosensor has thiolated ssDNA as a capture probe
immobilized on a Nafion–thionine–gold nanoparticle modi-
fied screen-printed electrode (SPE), which is hybridized with
a horseradish peroxidase (HRP)-labeled aptamer for detec-
tion. In the presence of TOA, there is a conformational
change in the aptamer and HRP labeled aptamer is released
from the complex in turn lowering the response current.
However, the biosensor was not effectively able to differen-
tiate between TOA and TOB, which directs towards finding
specific aptamers in the future (Luo et al. 2014).
Tuberculosis (TB) is a fatal disease spread worldwide.
Available diagnostic tests for TB are time consuming, ex-
pensive, or have low sensitivity, whereas aptamers with their
ability to be highly sensitive and specific can be apt as an
Table 1. Aptamers selected against Salmonella species
Bacteria Aptamer Kd Application Reference
S. typhimurium DNA 1.73±0.54 μM Dwivedi et al. 2013
S. typhimurium RNA 20 nM Aptamer-immobilized ELISA
and aptamer-linked
precipitation experiments
Han and Lee 2013
S. typhimurium DNA 3.0 nmol Moon et al. 2013
S. typhimurium DNA 6.33±0.58 nM Fluorescent bioassay Duan et al. 2013
S. paratyphi A DNA 47±3 nM Biosensor based on SWNTs
and DNAzyme-labeled
aptamer detection probes
Yang et al. 2013
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alternative diagnostic tool. Rotherham et al. (2012) selected
aptamers against the 10-kDa culture filtrate protein (CFP-10)
and the 6-kDa early secreted antigen target (ESAT-6), which
are potent T-cell antigens recognized in over 70% of TB
patients. In total six aptamers were selected against these
targets, which had Kd values in the nanomolar (nM) range.
The study suggested that aptamers are feasible for diagnosis
of active TB in human biological samples obtained from
patients with and without active TB (Rotherham et al.
2012). Similarly, Tang et al. (2014) selected aptamers for
CFP-10 and ESAT-6, which were able to detect these pro-
teins in serum. The authors suggest that these aptamers have
a broad range of application, as they were able to detect
CFP10 and ESAT6 in active pulmonary TB patients, extrap-
ulmonary TB patients and healthy donors by using an
enzyme-linked oligonucleotide assay (Tang et al. 2014).
Zhu and coworkers developed a sandwich ELISA based on
an anti-MPT64 antibody aptamer for the diagnosis of TB.
They used a combination of immunization and genetic engi-
neering to obtain an anti-MPT64 antibody, which was fur-
ther used as a target for SELEX. This method can be used for
the serological diagnosis of pulmonary TB, both in sputum
smear positive- and negative-patients, with a lower detection
limit of 2.5 mg/L (Zhu et al. 2012a). Surface plasmon
resonance-based SELEX (SPR-SELEX) was used to select
two RNA aptamers against EsxG protein with nM affinity.
This protein is a secreted substrate of the ESX-3 secretion
system. The ESX-3 secretion system is one of the complexes
of mycobacteria, which help the bacteria to grow in low iron
environments such as macrophages. Thus, specific aptamers
towards the EsxG protein can be used as molecular probes
for TB diagnosis (Ngubane et al. 2014).
2.2 Parasites
Trypanosoma cruzi causes Chagas disease, estimating about
6 million to 7 million people to be infected worldwide.
Nearly 30% of chronically infected people with Chagas
disease develop cardiac alterations and up to 10% develop
digestive, neurological or mixed alterations which may re-
quire specific treatment. The parasite has to invade the host
cells in order to cause the disease. This invasion is most
likely supported by the cell surface macromolecules laminin,
thrombospondin, heparan sulfate, and fibronectin. Therefore,
these molecules were used as targets for selection of
aptamers by Ulrich et al. (2002). The selected nuclease
resistant RNA aptamers showed specific binding affinities
in the 40-400 nM range and they were shown to inhibit
T. cruzi invasion in LLC-MK2 monkey kidney cells
in vitro (Ulrich et al. 2002). The currently available detection
method of T. cruzi in humans is PCR based and is only
sensitive at the acute stage of the disease when parasite
numbers are high in the blood. Thus, to improve the PCR
based method Nagarkatti et al. (2012) utilized a whole cell
SELEX method for the selection of serum stable RNA
aptamers against living T. cruzi trypomastigotes. The high
affinity aptamer Apt68 was found to be specific towards
T. cruzi trypomastigotes and it captured living parasites
when biotinylated and immobilized on solid phase. Apt68
was applied in collecting parasites from parasite-spiked
blood at low concentrations to facilitate the PCR based assay
for detection of T. cruzi (Nagarkatti et al. 2012). A combi-
natorial selection method was used to select RNA aptamers
against Trypanosoma using living Trypanosoma brucei par-
asites, which causes African trypanosomiasis. The selected
aptamers showed specificity towards a 42 kDa protein pres-
ent in the flagellar pocket of the parasite (Homann and
Göringer 1999). T. brucei escapes the host immune system
by antigenic variations in surface proteins known as variant
surface glycoproteins. Lorger et al. (2003) targeted these
variant surface glycoproteins and selected a serum stable
RNA aptamer with sub-nanomolar affinity. Bound with an
antigenic side group the aptamer was able to direct anti-
bodies towards the surface of the parasite in vitro (Lorger
et al. 2003). Furthermore, Homann et al. (2006) selected a
2'-NH(2)-modified RNA aptamer towards living trypano-
somes with an affinity at nanomolar range with a half-life
of more than 30 hours in human serum (Homann et al.
2006).
Leishmaniasis caused by Leishmania is another important
disease which severely affects millions of people worldwide.
Martín et al. (2013) used L. infantum KMP-11, LiH2A and
LiH3 proteins from Leishmania as targets. The two selected
aptamers had different secondary structures, but were able to
recognize the same peptides located on the side of the LiH2A.
These aptamers were able to detect the parasite on ELONA
platforms and were able to purify o LiH2A from complex
mixtures (Martín et al. 2013). Kinetoplastid membrane
protein-11 (KMP-11) is a widely distributed, conserved kinet-
oplastid and a major cell membrane component of kinetoplas-
tid parasites like Leishmania infantum. DNA aptamers were
selected against KMP-11 bound to colloidal gold during
SELEX processes intended for diagnostic purpose. The use
of colloidal gold added a higher mass to the protein in order to
be purified by centrifugation during the partition phase of the
SELEX process (Moreno et al. 2003).
The aptamer’s secondary structure plays an important role
in determining its specificity and high affinity towards the
target. Aptamers selected against lactate dehydrogenase of
Plasmodium falciparum, a causative agent of malaria, had a
dissociation constant of 42 nM. The crystal structure of the
protein-aptamer complex revealed two aptamers binding one
tetramer of the protein, where both of them displayed a distinct
hairpin loop structure involved in the binding with a Plasmo-
dium lactate dehydrogenase loop that is absent in human
lactate dehydrogenase. Furthermore, gold nanoparticles were
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conjugated to this aptamer for a colorimetric application to
detect malaria (Cheung et al. 2013).
2.3 Viruses
The usual methods for the detection of viruses are time con-
suming so a need for more efficient, specific and faster
technique is evident. Aptamers are a good solution in all
these aspects. For example, Parekh et al. (2010) used cell
SELEX to select aptamers against Vaccinia virus, since it is
closely related to smallpox virusVariola. The selected aptamer
was highly specific towards virus-encoded hemagglutinin
expressed on the surface of infected cells. Thus, aptamers
can be generated against a given specific infectious agent like
virus and can also be used for diagnostic purposes (Parekh
et al. 2010). For early detection of hepatitis C virus (HCV)
from patient’s sera a protein chip-based assay was developed.
Here, RNA aptamers specific for HCV core antigen were
immobilized on a sol-gel based material to form a biosensor,
and then patient sera along with Cy3-labeled human antibody
was applied for the detection of HCV infection. The RNA
aptamers showed stronger signals with the infected sera com-
pared to negative controls (Lee et al. 2007). Furthermore, a
functional ssDNA aptamer specific towards HCV envelope
surface glycoprotein E2 was screened by cell surface-SELEX.
The selected ZE2 aptamer showed highest specificity and
affinity to E2-positive cells from patient sera when tested with
the E2 antigen-aptamer assay, and assays for HCV RNA
quantification or HCV antibody detection. Sandwich ELISA
was used for virus capture assays using ZE2, indicating that
ZE2 aptamer can also bind to HCV and thus can be used for
capture and diagnosis of HCV (Chen et al. 2009a). After
treatment against HCV it is important to monitor efficacies of
potential anti-HCV drugs, for example by quantification of
HCV infectious units. The conventional foci counting method
is laborious and time-consuming, while other methods includ-
ing quantitative reverse transcriptase-PCR (RT-PCR) and im-
munological measurement of core proteins are not ideal either.
The viral RNA, which is measured by real-time RT-PCR
cannot correlate with the infectivity of a HCV sample, more-
over, immunological measurement of core proteins also fails
since core proteins exist in both infectious and noninfectious
HCV particles. A recently developed assay called ‘Enzyme
Linked Apto-Sorbent Assay (ELASA) for the quantification of
infectious HCV particles uses aptamers against the HCV E2
envelope protein (Park et al. 2013). ELASA utilizes two
different aptamers recognizing two different regions of HCV
E2, where one capture aptamer is attached directly to the
surface of a microtiter plate well and binds to E2 proteins on
the virus surface, while the other detection aptamer is biotiny-
lated. In the presences of HCV the biotinylated aptamer will
react with streptavidin conjugated with HRP correlating pro-
portionally to the amounts of HCV E2. This assay can also
monitor the activities of anti-HCV drugs. Liu and coworkers
were the first to report a RNA aptamer, which could bind to a
surface antigen (HBsAg) of Hepatitis B virus (HBV for the
diagnosis of the virus. They selected aptamer HBs-A22, which
binds specifically to the HBsAg expressing hepatoma cell line
HepG2.2.15, but did not bind to HBsAg-devoid HepG2 cells
(Liu et al. 2010).
Avian influenza viruses (AIV) have caused devastating out-
breaks worldwide with high mortality rates in both poultry and
humans. To contain spreading of the disease, quick and sensi-
tive diagnosis of H5N1 infections is essential. Currently avail-
able laboratory methods use conventional virus cultures
followed by serological differentiation, RT-PCR and real- time
RT-PCR, which are time consuming and demand technical
expertise as described earlier. As an alternative an aptamer
hydrogel based quartz crystal microbalance (QCM) biosensor
was developed by Wang and Li (2013) for the detection of
AIV H5N1. Specifically selected aptamer against AIV H5N1
surface protein was hybridized with ssDNA to form the cross
linker in the polymer hydrogel. Furthermore, the hydrogel was
immobilized on the gold surface of the QCM sensor, where the
hydrogel is in a shrunken state in the absence of the H5N1
virus due to the crosslinking between the aptamer and ssDNA
in the polymer network. Presence of H5N1 virus causes the
dissolution of the linkage between the aptamer and ssDNA
resulting in subsequent swelling of the hydrogel. The swelling
of the hydrogel is observed in terms of a decreased frequency
by the QCM sensor. The hydrogel QCM aptasensor has low-
ered the detection time twofold when compared with the anti-
H5 antibody coated QCM immunosensor, which takes an hour
(Wang and Li 2013). The influenza virus acquires new anti-
genicity with every outbreak, leading to the emergence of new
virus strains, for which new diagnostic tools must be devel-
oped rapidly to detect novel influenza strains. Shiratori et al.
(2014) developed DNA aptamers that bind to HA1 proteins of
multiple influenza A virus subtypes. A novel aptamer-based
assay for evaluating the binding properties of the selected
aptamers was developed. A microtiter plate well coated with
viral protein and flooded with HA1 specific biotinylated
aptamers is followed by the addition of streptavidin-HRP. In
this approach H5N1, H1N1, and H3N2 subtypes of influenza
A virus were detected (Shiratori et al. 2014). Bruno and cow-
orkers screened DNA aptamers against various virulent arbo-
viruses like Chikungunya, Crimean-Congo hemorrhagic fever
(CCHF), dengue, tick borne encephalitis andWest Nile viruses
using recombinant envelope proteins or synthetic peptides
and/or whole inactivated viruses. They showed the diagnostic
utility of some aptamers for arbovirus detection on the surface
of magnetic micro-beads, lateral flow chromatographic assays
and in fluorescent-based sandwich assay (Bruno et al. 2012).
Park et al. (2011) screened an aptamers against Hemagglutinin
(HA) which is present in the virus envelope. Antiviral efficacy
of the selected RNA aptamer HAS15-5, binding to HA1, was
Aptamers in diagnostics, drug-delivery and imaging 541
J. Biosci. 41(3), September 2016
determined by a hemagglutination inhibition assay using egg
allantoic fluids harboring the virus. This lead to blocking and
inhibition of viral HA, and thus can further be developed as a
diagnostic tool as well as a novel antiviral agent against type
H5 avian influenza virus (Park et al. 2011).
Drug-resistant variants of HIV-1 are also known to be
resistant to anti RT-RNA aptamers. Li et al. (2008) isolated
two aptamers against Mutant 3 (M3) from the multidrug-
resistant HIV-1 RT panel. These aptamers were able to bind
a new RNA-binding epitope on the surface of HIV-1 RT.
Using these aptamers, M3 and wild type HIV-1 RTs could
be distinguished using an aptamer based microarray which can
help in determining HIV-1 drug resistance. By probing protein
conformation as a correlation to drug resistance an additional
and useful measure has been introduced (Li et al. 2008).
Current diagnostic tools for the isolation of viruses during an
outbreak rely on serotyping. Several aptamers were selected
against the recombinant HA protein from swine Influenza A
virus (IAV) H3 cluster IV for a more rapid approach. From the
selected aptamers the HA68 aptamer was able to bind and detect
H3N2v isolated from recent human cases. This aptamer can be
used as a subtype-specific aptamer against Swine H3N2 IAVs
for fast detection and virus sero-typing (Wongphatcharachai
et al. 2013). Dengue fever is one of the prominent arthropod-
borne viral diseases and it can be detected by ELISA-based and
reverse transcriptase polymerase chain reaction methods. A
biosensor for the detection of the Dengue virus genome was
developed by Fletcher and co-workers which consists of three
modules: (a) detection of target the nucleic acid, (b) signal
transduction and (c) signal detection module. In the detection
module the target-of-interest is detected by a stem/loop linker
oligonucleotide. The loop portion is complementary to the
target-of-interest, while one of the strands of the stem duplex
(i.e. the trigger) is complementary to a portion of the aptamer
within the transducer module. The signal transducer comprises
an EcoRI inhibitory-aptamer complex. In the signal detection
module an oligonucleotide like molecular break-light (MBL) is
used. It consists of a stem/loop-forming unit with a 5′ fluoro-
phore and 3′ quencher with an EcoRI recognition sequence in
the stem duplex. When the dengue virus genome is present the
linker interacts with the signal transducer module and liberates
the restriction endonuclease EcoRI from aptamer-mediated in-
hibition. The active EcoRI molecule then cleaves multiple sig-
naling molecules by dissociation of the fluorophore and the
quencher resulting in a detectable signal. In this modular system
the linker can be changed for the target-of-interest, e.g. for the
detection of the four Dengue genome serotypes (DEN1-DEN4)
without modifying the signal transduction module (Fletcher
et al. 2010). Dengue virus enters the host cell through
receptor-mediated endocytosis with the help of envelope (E)
protein, cell surface receptors. The 395 residue E ectodomain
has three domains, namely EDI, EDII and EDIII (residues 295–
394), and the EDIII is possibly involved in host cell receptor
binding. A thioaptamers targeting this EDIII protein of dengue-
2 virus was developed by Gandham et al. (2014). This aptamer
DENTA-1 was able to bound DENV-2 EDIII which is adjacent
to a known neutralizing antibody binding site with a kd of 154
nM. Thus, can be used as potential candidate for diagnosis as
well as for antiviral drug discovery (Gandham et al. 2014).
DNA aptamers can also be used as a replacement of
antibodies to characterize the subtle conformational changes
in therapeutic proteins which might occur during pasteuriza-
tion step of manufacturing. Early detection of these subtle
conformational changes is important for safety, stability and
efficacy of the therapeutic protein. It has been previously
shown that heat treatment does not affect the protein activity;
however, the resulting conformational changes cannot be
detected by antibodies. To address this issue, Zichel et al.
(2012) developed a panel of aptamers for the detection of
conformational changes in thrombin after heat treatment.
These aptamers were also used in both ELISA and label-
free platform type assay to characterize different thrombin
products (Zichel et al. 2012).
2.4 Cancer
Biomarkers for specific diseases are an important tool for the
timely and effective management of pathological conditions,
including determination of susceptibility, diagnosis, and
monitoring efficacy of preventive or therapeutic strategies.
Early detection of cancer is crucial in oncology. In this
aspect, aptamers play a crucial role in screening against
particular cancer cell biomarkers. When biomarkers and
efficient tools like specific aptamers with high affinity are
merged, an effective tool to detect their interaction using a
sensor is needed, e.g. an aptasensor. Thus, numerous apta-
sensors were developed recently which facilitate the detec-
tion of various cancers at an early stage. In this section, we
discuss about the aptamer mediated diagnostic tools for
cancer detection, categorized according to the cancer
subtype:
2.4.1 Breast cancer detection: Human mucin-1 (MUC1) and
vascular endothelial growth factor-165 (VEGF-165) are
important biomarkers for the diagnosis of breast cancer.
Elevated levels of MUC1 in breast cancer is associated
with its recurrence and increased lymph node metastases
(Mukhopadhyay et al. 2011), while overexpression of
VEGF is related to increased mortality in lymph node-
negative and lymph node-positive breast cancer patients
(Ghosh et al. 2008). Many aptasensors have been devel-
oped using these two biomarkers for the assessment of
breast cancer. Previously discovered aptamers for MUC1
and VEGF165 were used by Zhao et al. (2012a) for the
development of so called ‘signal-on’ electrochemical
aptasensors. This aptasensor has a Fc-labeled cDNA-
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fragment, immobilized on a gold electrode, with a com-
plementary binding site for MUC1 and VEGF165
aptamers. In absence of MUC1 and VEGF165 bio-
markers the aptamers are hybridized with the cDNA-
fragment to form a long double strand that keeps Fc-
molecules away from the electrode surface, resulting in no
signal. In the presence of only one of these biomarkers, one
of the aptamers will be detached from the cDNA-fragment,
thus, reducing the distance between electrode surface and the
Fc-molecule, resulting in a minor signal. However, in the
presence of MUC1 and VEGF165, both, the aptamers bind
to their respective targets, triggering the reduction of distance
between the electrode and the Fc-molecule due to stem loop
formation by the ss-cDNA-fragment, resulting in a stronger
signal. The method of using two tumor markers over only one
can be expanded to other types of tumors by changing the
aptamers for their respective targets (Zhao et al. 2012a).
Another sensing platform developed by Zhao et al. (2012)
uses aptamers and RNA polymerase-based amplification for
the detection of Michigan cancer foundation-7 (MCF-7)
breast cancer cells. In this assay, a biotinylated aptamer
specific to MUC1 was immobilized on a microtiter plate
well using streptavidin that captures tumor cells (i.e. recog-
nition probe). To this, a complex oligonucleotide, composed
of a MUC1 aptamer region and single-stranded T7 RNA
polymerase promoter (ssPr), is added to form a sandwich
structure. A template probe comprised of complimentary
ssPr and a template sequence hybridizes with the ssPr region
of the recognition probe forming a double-stranded T7 RNA
polymerase promoter site (dsPr). Finally, T7 RNA polymer-
ase can attach and generate multiple copies of RNA strands
which in turn are detected by the addition of SYBR Green II
dye. The cell concentration is determined by the fluores-
cence intensity with 500 cells/mL limit of detection (LOD)
(Zhao et al. 2012b).
Furthermore, a signal-on fluorescence aptasensor was
developed for label-free detection of MCF-7 breast cancer
cells. This sensor uses a MUC1 specific aptamer which
binds MCF-7 cells and is then removed by centrifugation.
A signal probe complementary to anti-MUC1 aptamer is
added to the supernatant along with terbium (III) (Tb3+), as
ssDNA subsequently enhances the emission of Tb3+. How-
ever, the lack of MCF-7 cells results in hybridization of the
signal probe with aptamer forming ds-DNA. The ds-DNA
cannot increase the emission intensity of Tb3+ compared to
ssDNA. This signal-on aptasensor has a LOD of 70 cells/
mL (Cai et al. 2015).
A label-free and electrical detection of vascular VEGF
using anti-VEGF aptamer-modified Si nanowire field-effect
transistors (SiNW-FETs) was developed for breast cancer
diagnosis. SiNW-FET biosensors were prepared by immo-
bilization of anti-VEGF aptamers on the surface of modified
single-crystalline SiNWs (n-type and p-type). Since the
VEGF molecules are positively charged under experimental
conditions at pH 5.4 (the iso-electric point of VEGF is 8.5),
they are effectively screened against RNA aptamers due to
their negative charge. The resulting charge depletion in the
nanowire channel and the decrease in conductance in case of
the p-type Si nanowire biosensors were observed. However,
this positive gate voltage by VEGF had the opposite effect
on the device in case of n-type Si nanowire biosensors. The
LOD of the VEGF biosensor was ~1 nM for n-type and 100
pM for p-type SiNW-FETs (Lee et al. 2009). In addition, for
detection of breast cancer, a new quantitative immunohisto-
chemistry (QIHC) microfluidic polydimethylsiloxane
(PDMS) platform was developed with aptamer as a reporting
probe specific to the Fc region of IgG antibodies. The micro-
fluidic PDMS platform harbors breast cancer cells in paraffin
block-slides to form a micro-reaction chamber. Primary anti-
bodies specific to breast cancer marker proteins were loaded
followed by the aptamer. The marker proteins were quanti-
fied by real time amplification of the aptamers using quan-
titative nucleic acid sequence based amplification, resulting
in detection of cancer proportional to the concentration of
different primary antibodies for marker proteins. This micro-
fluidic platform was also used for aptamer-assisted IHC for
breast cancer cell lines and showed good correlation with
conventional IHC (Yeong Won et al. 2013).
Another electrochemical technique based on the aptamer–
cell–aptamer sandwich architecture for the detection of
MCF-7 human breast cancer cells was based on immobilized
MUC1 aptamer on a gold electrode. In the presence of target
cells and after incubation with the HRP-labeled MUC1
aptamer, the electrochemical response is catalysed by HRP,
with the help of thionine, an electron mediator. The LOD for
this technique was 100 cells/mL (Zhu et al. 2013a).
A selective electrochemical diagnosis of breast cancer
was developed by Zhu and coworkers based on a hydra-
zine–Au nanoparticle–aptamer bioconjugate (Hyd–AuNP–
Apt), where the aptamer is specific toward human epider-
mal growth factor receptor 2 (HER2), which is overex-
pressed in breast cancers. Here, hydrazine, capable of
reducing silver ions to silver metal is attached to AuNPs
and aptamer to form Hyd–AuNP–Apt. The sensor probe
has a monoclonal anti-HER2 antibody immobilized on
electrode, which is the nanocomposite surface with self-
assembled DPB (2, 5-bis (2-thienyl)-1H-pyrrole-1-(p-ben-
zoic acid)) and AuNPs attached to indium tin oxide coated
glass. During the detection of HER2-overexpressing SK-
BR-3 breast cancer cells, a sandwich is formed between the
sensor probe, HER2 expressing cells and Hyd–AuNP–Apt,
which is then treated with silver nitrate solution where
silver ions are reduced by hydrazine and deposits onto the
breast cancer cells. This deposited silver on breast cancer
cells can be observed under a microscope and analysed
using square wave stripping voltammetry to determine the
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amount of HER2 cells with a LOD of 26 cells/mL in human
serum samples (Zhu et al. 2013b).
2.4.2 Cervical cancer: In case of cervical cancer, most of
the carcinogenesis is caused by human papillomavirus
(HPV) infection, which may or may not lead to carcino-
genesis and, hence, there is need to find biomarkers that
differentiates the two. For this purpose, Graham and Zarbl
screened a panel of aptamers against cell surface epitopes
of human cervical cancer using a HeLa cell line for whole
cell SELEX and isogenic HeLa cells for negative selection.
The aptamers had a high affinity for epitopes specific to the
cell surface of non-tumorigenic revertants derived from the
human cervical cancer HeLa cell line, but did not bind to
the HPV transformed cervical cancer cell line. This indi-
cated that the aptamers are specific for epitopes that were
lost during HPV induced transformation of the cervical
cells and can be used to identify new biomarkers that are
related to carcinogenesis and for diagnosis (Graham and
Zarbl 2012).
2.4.3 Burkitt lymphoma detection: Burkitt lymphoma diagno-
sis is challenging due to its morphologic overlap with diffuse
large B cell lymphoma and the person’s level of experience
performing diagnosis (Rane et al. 2014). Shi et al. (2010) were
the first to report molecular engineered aptamers with signaling
molecules for fluorescence imaging of specific tumor cells in a
mouse, for which, a known aptamer, TD05, specific against
Ramos cells – a human Burkitt’s lymphoma cell line – was
used. The specificity of the TD05 aptamer was tested via
labelling with Cy5 dye. Cy5-TD05 aptamer along with control
Cy5-Sgc8a and Cy5 dye alone were injected into mice harbor-
ing a Ramos tumor. The authors observed that Cy5-TD05
accumulated in the Ramos tumor while Cy5 dye and the control
probe Cy5-Sgc8a were gradually cleared from mice (Shi et al.
2010). For visualized detection of Ramos tumor cells a chemi-
luminescence imaging array (CLIA) strategy alongwith a com-
bination of tumor cell aptamer recognition and amplification of
bio-bar-code nanotechnology with rolling circle amplification
(RCA) for signal amplification was used. The aptamers TD05
and TE02 bind specifically to Ramos cells and were used in the
CLIA. Biotinylated TE02 was attached to a streptavidin-coated
96-well microtiter plate as a capture aptamer, and thiol-TD05
was immobilized on the AuNPs along with circular DNA
templates as bio-barcodes hybridized with primer for recogni-
tion of cells and to avoid cross-reactions. Upon addition of
Ramos cells on the CLIA a sandwich assay format is formed
to give a AuNP-TD05aptamer-cell-TE02 aptamer complex.
When Klenow DNA polymerase and dNTPs are added to this
complex a RCA is initiated on the AuNPs which produces a
long ssDNA with tandem-repeat sequences, which bind to
biotinylated detection probes. This biotinylated probe further
binds to streptavidin–HRP to which luminol–H2O2–PIP is
added for 10 min and visual detection is performed by observ-
ing the chemiluminescence intensity. Quantitative analysis was
done by using analysis software for reading the optical intensity,
and 3 σ was used to detect LOD at 163 Ramos cells/mL. Even
with the complexity of the method, the authors claim it to be an
operationally robust, easy and cost-effective strategy (Bi et al.
2013).
2.4.4 Multiplexed cancer cell detection: Chen et al. (2009b)
developed an aptamer-conjugated fluorescence resonance en-
ergy transfer (FRET)-nanoparticles (NPs) assay for the detec-
tion of simultaneous multiplexed monitoring of cancer cells.
They used the sgc8 aptamer for CEM cells (human acute
lymphoblastic leukemia cells) conjugated to a NP (FAM-
R6G), the TDO5 aptamer against Ramos cells (human Bur-
kitt’s lymphoma cells) coupled with a NP (FAM-R6G-ROX),
and the T1 aptamer for Toledo cells (human diffuse large cell
lymphoma) coupled to a NP (FAM). These conjugated
aptamers when added to cancer cells were able to bind specif-
ically to the respective cells (Chen et al. 2009b).
Viraka Nellore et al. (2015) reported for the first time an
efficient capture and accurate identification of multiple types
of circulating tumor cells (CTCs) from infected blood using
aptamer-modified porous graphene oxide membranes. They
used Cy2-modified S6 aptamer that binds specifically to
HER2 biomarker for breast cancer CTCs, Cy5-modified
A9 aptamer that binds to prostate-specific membrane antigen
(PSMA), a biomarker for prostate cancer CTCs, and the
Alexa Fluor 488 dye modified YJ-1 aptamer specific to-
wards CEA biomarker for colon cancer CTCs. These three
aptamers were conjugated to porous graphene oxide mem-
branes, where graphene oxide is an efficient quencher and,
thus, when dye conjugated aptamers are attached to gra-
phene oxide, fluorescence from dye gets quenched by gra-
phene oxide. In principle, when the dye-conjugated aptamer
binds to targeted cancer cells the distance between the dye
and graphene oxide increases resulting in fluorescence. This
graphene oxide membrane conjugated with aptamers was
able to capture multiple types of tumor cells selectively and
simultaneously from infected blood and was also able to
identify captured cancer cells via multicolor fluorescence
imaging (Viraka Nellore et al. 2015).
2.4.5 Cancer detection using common biomarkers:Many cell
surface cancer biomarkers are common in a variety of cancers,
e.g., nucleolin, carcinoembryonic antigen (CEA), HER-2,
epithelial cell adhesion molecule (EpCAM) etc. Taking advan-
tage of this information many aptamers have been developed
against these biomarkers, which serve as a diagnostic tool for
the generic detection of these cancer types. We have discussed
some of these recently developed aptamers and aptasensors
below.
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The cancer biomarker nucleolin is overexpressed on the
plasma membrane of tumor cells as compared to normal
cells. To detect cancer cells Feng et al. (2011) used aptamer
AS1411, specific for nucleolin, to develop a label-free de-
tection method based on a graphene electrochemical-apta-
sensor, which was utilized in the phase II clinical trial.
Perylene tetracarboxylic acid (PTCA) was used to function-
alize chemically converted graphene, and the NH2-modified
aptamer strand was linked to it by a carbodiimide-mediated
wet-chemistry approach. These aptamer-PTCA nanocompo-
sites were used as nanoscale anchorage substrates to capture
tumor cells on the electrode surface. Electrochemical imped-
ance spectroscopy (EIS) was then used to monitor change in
electron transfer resistance. Addition of AS1411 comple-
mentary DNA (cDNA) hybridized with the aptamer and
disrupted aptamer-tumor cell binding, regenerating the sen-
sors. The LOD for HeLa cells was calculated to be 794 cells/
mL at 3 σ (Feng et al. 2011).
Highly glycosylated CEA is another over-expressed pro-
tein in a large number of tumors. An electrochemical
aptamer biosensor was designed by Shu and coworkers
based on the signal amplification of AuNPs for the detection
of a CEA. In this biosensor CEA is sandwiched between an
Au electrode with thiol-terminated CEA aptamer-1 and the
AuNPs with thiol-terminated CEA aptamer-2 and 6-
ferrocenyl hexanethiol (Fe). The concentration of CEA was
determined by the detection of Fe by differential pulse vol-
tammetry with a LOD of 0.5 ng/mL (Shu et al. 2013).
Recently, a new method was developed for radiolabelling
aptamers with 99mTc where the two aptamers - Apt3 and
Apt3-amine - selected against the well characterized human
tumor associated antigen CEA were used. In binding assay
the radiolabeled aptamer showed high specificity and affinity
to T84 cells making the aptamer a promising agent for the
identification of CEA present in tumor cells (Correa et al.
2014). One more method was developed for the detection of
CEA by capillary electrophoresis (CE) which is based on the
combination of graphene oxide (GO) and quantum dots
labeled with aptamer (QD–aptamer). Addition of CEA to
the QD–aptamer forms QD–aptamer-CEA complex. Since
the CE peaks for the QD–aptamer are close to the QD–
aptamer–CEA, to reduce this, GO is first added to the QD–
aptamer, which quenches its fluorescence. The QD–
aptamer–CEA complex could not bind to GO stably, hence,
gets separated by CE, which in turn improves the fluores-
cence. The LOD for this method was approximately 5 pg/mL
(Zhou et al. 2014).
A label-free and turn-on aptamer strategy for cancer cell
detection was developed by Yin and colleagues. This strat-
egy involves two probes; a signal probe (S-Probe) tailored
with DNA template with dark silver nanoclusters (Ag-NCs)
and a link sequence complementary to the arm segment of
the recognition probe (R-Probe). The R-Probe includes a
central target-specific aptamer sequence at the 3’-end, a
guanine-rich DNA sequence and an arm segment at the 5’-
end forming a hairpin structure due to hybridization of the
arm segment with its complementary part of the aptamer
sequence in absence of target cells. In the presence of target
cancer cells, aptamer binds to the protein receptors on the
cancer cells enforcing conformational changes in R-Probe
and causing the arm segment dissociation, followed by hy-
bridization between the arm segment and the link sequence
in the S-Probe. This brings S-Probe templated dark Ag-NCs
close to the guanine-rich DNA sequences of the R-probe
resulting in enhanced fluorescence. In particular, this strate-
gy was used for the detection of CCRF-CEM cancer cells
using sgc8c aptamer and, in general, it has the potential for
being a simple, sensitive, universal and specific cancer cell
detection method (Yin et al. 2013).
EpCAM is overexpressed in most adenocarcinomas, can-
cer stem cell and metastases CTCs (Bellone et al. 2009).
Song and coworkers screened DNA aptamers that selectively
bind human recombinant EpCAM protein and these
aptamers were able to detect live human cancer cells derived
from breast, colorectal, and gastric cancers expressing
EpCAM. One of the selected SYL3 aptamer was optimized
in length to improve its binding ability which was also able
to detect target cancer cells from mixed cells in cell media
(Song et al. 2013).
A single-step single aptamer-based surface-enhanced
fluorescent optical sensor was developed for the detection
of a biomarker of cancer angiogenesis i.e., VEGF165. The
aptasensor uses a combination of an aptamer-target interac-
tion and nanoplasmonic-fluorophore interaction for target
recognition and for signal enhancement respectively. When
clinical samples of serum and saliva were tested, the apta-
sensor results for VEGF165 were in agreement with the
limits of the ELISA kit (Cho et al. 2013).
2.4.6 Circulating tumor cell detection: For the detection,
diagnosis, and monitoring of CTCs a method based on
aptamer-functionalized hydrogels and restriction endonu-
cleases was proposed by Li and coworkers. CCRF-CEM cells
(CL-119, human T lymphocytic leukemia cell line) were used
as a model cell line for this assay method. Here, hydrogel
functionalized with aptamer was able to capture target cancer
cells with a density over 1000 cells/mm. The hydrogel coating
was regenerated by treatment with restriction endonucleases
due to sequence-specific hydrolysis of the aptamer. Moreover,
98% of the released cells were viable with release efficiency
reaching 99% (Li et al. 2013).
2.4.7 Metastatic hepatocellular carcinoma detection: Hepato-
cellular carcinoma (HCC) has the tendency for metastasis and,
hence, to arrest it, an early prediction of metastasis is necessary.
To address this issueWang et al. selected aptamers against HCC
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cell line HCCLM9 with high metastatic potential and used
MHCC97-L cell line with low metastatic potential as a control.
When labeled with FITC, selected aptamer LY-1 was able to
detect HCC cells in simulated peripheral blood environment.
They also successfully used biotinylated LY-1 aptamer to cap-
ture CTCs using streptavidin coated magnetic beads in periph-
eral blood environment (Wang et al. 2013).
2.4.8 Colon cancer metastasis at lymph node: Colon cancer
leads to metastasis most of the time. Utmost the tumor
progression to metastasis is through entry of tumor cells
into the circulatory system like lymphatic channels. Li
et al. (2015a) developed DNA aptamers that specifically
bind to SW620 colon cancer cells derived from metastatic
site-lymph node. Selected DNA aptamer XL-33-1 was trun-
cated to 45 nt and showed specificity towards SW620 with
the binding target proposed to be a membrane protein on the
cell surface. To specifically recognize lymph node tissue
with colon cancer metastasis XL-33-1 aptamer was FAM-
labeled which showed bright green fluorescence after incu-
bating with the colon cancer tissue with metastasis in region-
al lymph nodes, and lymph node tissue with colon cancer
metastasis (Li et al. 2015a).
2.4.9 Gastric carcinoma detection: Human gastric carcinoma
is the most commonmalignant cancer due to lack of premature
state detection methods. To overcome this, aptamers were
selected against human gastric cancer cell line SGC7901 for
high affinity and specificity using cell-SELEX. The specificity
of selected S1a and S4a aptamers labeled with Cy5- fluoro-
phore at the 5′ end and the quencher group BHQ2 at 3′ was
verified by detecting clinical samples of human gastric tumor
tissues and normal human gastric tissues, where tumor tissue
gave bright red fluorescence with negligible signal from nor-
mal tissue. Furthermore, for the CTCs capture of SGC7901
cells a fluorescent-magnetic multifunctional nanospheres
(FMNS) were prepared by mixing Nano-γ-Fe2O3 particles,
QDs and ethanol-dehydrated nanospheres which were conju-
gated with streptavidin and subsequently, selected S4a bioti-
nylated aptamers were functionalized with the streptavidin-
FMNS. This assay showed a capture efficiency of 93% for
SGC7901 cells compared to 7% of control cells. The aptamers
also showed potential for in vivo testing as confirmed by the
in vivo study in mice (Ding et al. 2015).
2.4.10 Lung cancer detection: Late diagnosis of lung cancer
has become a major cause of cancer death since in the
advanced stage the curative treatment is no longer possible
(Detterbeck et al. 2013). Hence, there is an urgent need to
develop tools for diagnosis of this cancer at an early stage. In
this regard, Kunii et al. (2011) selected aptamers against
small cell lung cancer adherent SBC3 cell line. The aptamers
were evaluated and identified by fluorescent confocal
microscopy and flow cytometry. The selected aptamers pref-
erentially bound to intercellular junctions of SBC3 cells with
the ability to be used as a detection probe (Kunii et al. 2011).
In another study, Zhao and coworkers performed cell-
SELEX to obtain four aptamer probes against a subtype of
non-small cell lung cancer (NSCLC), i.e., adenocarcinoma.
They used A549 cell line (NSCLC, adenocarcinoma) for the
positive selection and HLAMP (NSCLC, large cell carcinoma)
cell line for counter selection by cell-SELEX. When the
aptamers were tested with clinical tissue sections representing
various subtypes of lung cancer, three of them showed a
significantly stronger fluorescence with adenocarcinoma tissue
sections compared to other lung cancer sections (Zhao et al.
2009). Hence, these aptamers have paved a way for early
detection and treatment of adenocarcinoma subtype of NSCLC.
2.4.11 Leukemia detection: Sefah et al. (2009) selected
aptamers against acute myeloid leukemia (AML) cells using
cell-SELEX. One of the selected aptamers, KH1C12, showed
selectivity towards AML cell line (HL60) compared to control
cell lines K562 and NB4, and was able to recognize the target
cells within a complex mixture of normal bone marrow aspi-
rates (Sefah et al. 2009).
2.4.12 Prostate cancer detection: Prostate cancer occurrence
has been increasing recently. The early diagnosis of this cancer
involves a prostate biopsy test, a microscopic examining
process, but is not used in all cases as it may cause acute
pain for patients. Other tests, digital rectal examination
(DRE), blood test for prostate specific antigen (PSA) and trans
rectal ultrasonography (TRUS), are prone to errors due to the
indirect process. To overcome these limitations Min and cow-
orkers designed a dual-aptamer probe, conjugating A10 RNA
aptamer to DUP-1 peptide aptamer for detection by an elec-
trochemical impedance spectroscopy (EIS) sensor. Biotin-A10
aptamer with 2’-F modified pyrimidines for the PSMA (+) cell
line and a biotin-DUP-1 peptide aptamer for the PSMA (-) cell
line were immobilized to streptavidin to form a dual-aptamer
probe. These aptamers were conjugated to a Au electrode, to
which, samples containing prostate cancer cells were added.
Due to difficulty of charge transfer through physical blocking
by bound cells to the aptamer probe on the electrode surface,
impedance increases. The authors expect this sensitive elec-
trochemical approach to be used for preliminary diagnosis of
prostate cancer with an advantage of being a non-painful
biopsy test (Min et al. 2010).
2.4.13 Glioblastoma detection: Glioblastoma is the most
common and malignant brain tumor with short survival and
fatal outcome even after treatment, and is associated with
morphologic, genetic, and gene-expression heterogeneity
(Olar and Aldape 2012). Two aptamers named GBM128 and
GBM131 were selected against cultured human glioblastoma
546 Chetan Chandola et al.
J. Biosci. 41(3), September 2016
cell line U118-MG using cell-SELEX. These aptamers were
also able to differentiate between clinical glioma tissues and
normal brain tissues. The binding affinity and selectivity of
these two aptamers were also retained in biological environ-
ment and, thus, can be used for early detection of glioblastoma
(Kang et al. 2012).
3. Aptamers for drug delivery
There are various methods for delivering drugs or bio-
molecules in cells for the therapeutic purposes. Histori-
cally, payloads have been delivered to the target cells
using liposomes, microspheres, nanofibers, antibodies or
peptides. However, these drug delivery carriers have
their own limitations, most commonly non-specificity,
or sometimes lower tissue penetration in case of anti-
bodies and peptides. In this regard, aptamers have
emerged as a new class of drug delivery tools that carry
very high specificity, lacking immunogenicity, and have
higher tissue penetration, which are imperative pre-
requisites for a good drug delivery vehicle. Also, less
challenging process of industrial synthesis gives them an
advantage over antibodies or peptides in terms of being
more economical to synthesize. Aptamers are easy to
synthesize, and it takes a short time, i.e., 3 months on
average to obtain a novel aptamer through the process of
SELEX (Sefah et al. 2010), with less batch to batch
variability than existing tools.
There are some challenges in using aptamers for thera-
peutic purposes as well. Aptamers are susceptible to nucle-
ase degradation, especially RNA aptamers, because the
nucleases are present in serum. However, this problem can
be overcome by chemical modifications in the sugar unit of
the phospho-sugar backbone of aptamers either post-
selectively or during the synthesis step of SELEX. Modifi-
cations include replacement of the 2′-OH group of ribose
sugar with 2′-fluoro, 2′-O-methyl or locked nucleic acids
(LNAs) (Behlke. 2008). Also, the phosphate backbone of
nucleotides can be replaced with phosphorothioate (Green
et al. 1995) or boranophosphate (Keefe and Cload 2008) to
reduce the nuclease affinity. Additionally, binding PEG
(polyethylene glycol) to the aptamers can increase the half-
life of the aptamer in physiological environment (Tucker
et al. 1999). In the last decade there has been a significant
growth in the efforts towards using aptamers as a tool for
drug delivery, using various payloads. Below, we have dis-
cussed some significant works where aptamers have been
used with different conjugates, or alone, to increase their
efficiency for targeted delivery (figure 3). A table (table 2)
shows recent work from the last five years where aptamers
have been used as a drug delivery tool.
3.1 siRNA and other oligonucleotide conjugated aptamers
The use of oligos such as siRNAs, miRNAs, shRNA as
an effective tool to inhibit the expression of comple-
mentary RNA transcripts is being used as a new class
of therapeutics for diseases including cancer and HIV.
However, the successful intracellular delivery of the
oligos to a specific cell type is one of the stumbling
blocks towards their use as a therapeutic agent. Also,
their anionic charge is an impediment to their entry into
the cells, and hence, various transporters, viz., lipo-
somes, cationic nanoparticles, antibodies and cholesterol
conjugates are used for the i r t rans-membrane
movement.
Aptamers have been used with oligos recently for
their specific delivery. The advantage of using aptamers
with oligos is their relative ease of synthesis because
they can be attached to the aptamer by extension of the
RNA aptamer, thus, circumventing the need of conjuga-
tion or purification steps. Such constructs are called as
aptamer-siRNA chimeras (AsiCs) as they represent the
combination of two noncoding nucleic acids with differ-
ent functions. The first si-RNA-aptamer conjugates were
produced by Ellington et al. (Chu et al. 2006) and
Sullenger et al. (McNamara et al. 2006) using two
different approaches. Since then, many works have been
done showing the role of aptamer-siRNA conjugates as
therapeutic agents.
In one such example, an aptamer against CTLA4
surface antigen in both tumor associated T-cells and
tumor cells helped in the successful internalization of
siRNA against STAT3 gene resulting in an inhibition
of tumor growth and metastasis (Herrmann et al.
2014). Also, AS1411 aptamer has been used along with
PEGylated liposomes to target nucleolin protein for the
delivery of siRNA targeting BRAF gene to prevent
melanoma. This in vitro study was extended to in vivo,
where A375 tumor xenograft mice showed inhibition of
melanoma growth on using siRNA conjugated AS1411
aptamer (Li et al. 2014b).
Controlled delivery of a drug to target cells has been
a challenge since long. To overcome this problem, a
group used an anticancer drug, doxorubicin (Dox),
bound nanocarriers capped with a programmable DNA
hybrid. This DNA hybrid consisted of an aptamer
against nucleolin and an antisense oligonucleotide for
miR-21 both of which are overexpressed in cancer cells.
Here, after the nanocarriers undergo aptamer mediated
endocytosis, the overexpressed endogenous miR-21
unlocks the nanocarriers by competitive hybridization
with the DNA hybrid leading to a sustained lethality
of cancer cells with maximum therapeutic efficacy and
minimal side effects (Zhang et al. 2014b).
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In addition to cancer, siRNA-aptamer conjugates have
also been used in countering AIDS. A chimera of DNA
aptamer and siRNA has been used to efficiently knock down
the expression of exogenously expressed HIV1 protease
gene (HIV-PR) in CD4+ T cells (Zhu et al. 2012b). In
another study, a group was successfully able to conjugate
and deliver a siRNA conjugated to a RNA aptamer into the
HIV1 infected cells. They tagged an aptamer against gp120,
a protein that is present on HIV-1 envelope and helps in the
entry of HIV-1 into the CD4 cells, to the si-RNA. This
gp120 aptamer-siRNA conjugate acted as a dual function
chimera, where both the aptamer and the siRNA had potent
anti-HIV activity that prevented HIV-1 infectivity (Zhou
et al. 2011).
Figure 3. Aptamers are either used alone or in conjugation with nanoparticles, liposomes/micelles and antibodies to increase their
specificity for targeted delivery of various payloads, viz. drugs, siRNAs or miRNAs.
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3.2 Nanoparticle conjugated aptamers
Use of aptamers along with nanoparticles has seen a sub-
stantial growth in the last decade. Aptamer functionalized
nanoparticles have been used in recent years for better tar-
geting and increased delivery of drugs for various diseases,
especially cancer. As a result of multivalent binding,
aptamer-nanoparticle conjugates have higher binding affini-
ties to targeted cells as compared to free aptamers (up to
1,70,000 fold) (Zhou et al. 2015).
During a targeted delivery, the aptamer binds to a specific
cell surface protein, thereby increasing the specificity of the
therapy. Thus, the drug is delivered only to the specific set of
cells bearing the aptamer specific target protein, increasing
the potency of localized delivery. Therefore, in contrast to a
systemic therapy, the local concentration of the drug can be
increased while side-effects to the healthy cells can be
reduced.
Drug release, in addition to specific targeting by a deliv-
ery vehicle, is an important aspect of drug therapeutics. To
this aim, a group used aptamers along with nanotechnology
in the field of cancer therapeutics. This group synthesized a
hollow gold nanosphere (HAuNS) that was bound with a
biomarker specific aptamer and the drug doxorubicin for
internalization and cytotoxicity in tumor cells respectively.
This conjugate (Apt-HAuNS-Dox) was stable at the biolog-
ical pH7.4 but at the low pH 5.0 in lysosomes, after inter-
nalization, aptamer releases Dox that selectively kills tumor
cells (Zhao et al. 2013). On the same principle, aptamer-
functionalized calcium carbonate (CaCO3) nanostructure
(Apt-CCN) resulted in pH dependent release of drug doxo-
rubicin, i.e., at low pH on entering lysosomes of target cells
(Zhou et al. 2015). In addition, photodynamic therapy (PDT)
(Shiao et al. 2014), miRNA (Zhang et al. 2014b) and ATP
(Mo et al. 2014) have also been used as an alternative for the
controlled release of a drug to the cancer cells.
In another work, EpCAM targeted aptamers conjugated
with Dox loaded PEG-PLGA polymerosomes were used
against adenocarcinoma cell lines successfully. Since
EpCAM is a cancer stem cell marker, this conjugate can
improve the specificity to EpCAM positive cancer cells
(Alibolandi et al. 2015). The overexpression of EpCAM
has been capitalized for the targeting and delivery of many
other drug-aptamer-nanoparticle conjugates for cancer ther-
apeutics, e.g., retinoblastoma (Subramanian et al. 2012) and
hepatocellular carcinoma (Pilapong et al. 2014). Also, a
targeting supported by aptamers along with nanoparticles
has been utilized for the nuclear uptake of an anticancer
drug, specifically for the treatment of multidrug resistant
cancers (Qiu et al. 2015).
In some studies, success has been observed also at the
in vivo level. In one such study, Balb/c mice were injected
with CD26 cells for colon cancer tumor progression. After a
sizeable tumor formation they were treated with epirubicin
loaded 5TR1 aptamer functionalized super paramagnetic
iron oxide nanoparticles (SPION), which was able to signif-
icantly reduce the tumor growth in vivo (Jalalian et al. 2013).
Similarly, Yu et al. were also able to show selective drug
delivery in LNCaP xenograft mouse model. They used a
doxorubicin conjugated PSMA aptamer functionalized ther-
mally cross-linked superparamagnetic iron oxide nanopar-
ticles (TCL-SPIONs). The advantage of this Dox-Apt-hybr-
TCL-SPION conjugate was that super paramagnetic iron
oxide nanoparticles facilitated the MRI of the target tumor
tissue while Dox conjugated aptamer resulted in tumor cyto-
toxicity in vivo (Yu et al. 2011).
3.3 Micelles and liposomes conjugated aptamers
Though there has been significant development in the field
of nanotechnology in the last decade, some challenges in
their clinical application still persist. Firstly, nanoparticles do
not have very satisfactory physico-chemical properties,
mainly because of tedious preparation process, low drug
loading, and poor stability. Secondly, although NPs reach
the target cells by enhanced permeability and retention
(EPR) effect, their non-specific uptake by the mononuclear
phagocytic cells of liver, spleen and lungs may cause severe
side effects.
Among all nanoparticle based drug delivery systems, lip-
osomes are the most suitable to be used for clinical purpose.
They are biocompatible, stable, easy to synthesize, have a
low batch-to-batch variation, stable, high drug payload and
could carry one or more therapeutic molecules. Liposomes
have earlier been used in cancer cell targeting with chemo-
therapeutic payloads based on the principle of enhanced
permeability and retention. However, this principle has a
drawback that liposomes cannot differentiate between nor-
mal and diseased cells, and can be taken up by non-target
cells causing serious side effects. Hence, aptamers have been
used to functionalize liposomes for the targeted delivery of
drugs to the diseased cells causing higher cytotoxicity and
minimize the off-target side effects.
In one of the studies, doxorubicin loaded AS1411
aptamer (Ap) functionalized pluronic F127/cyclodextrin
linked polymer composite micelles (CM) were used and
studied both in vitro and in vivo. In vitro, CM-Ap showed
higher cellular uptake and reduced proliferation due to the
nucleolin-mediated endocytosis as compared to the control.
In the in vivo study involving MCF-7 tumor bearing mice the
CM-Ap showed extended circulation time in blood, im-
proved antitumor activity, decreased cardiotoxicity and bet-
ter accumulation in tumor. Thus, aptamer-conjugated
composite micelles could be used as potential anticancer
targeting vehicles (Li et al. 2015b).
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Table 2. List of aptamer mediated drug delivery systems for therapeutic purposes
a. siRNA and other oligonucleotide conjugated aptamers
Aptamer type Aptamer target Cargo Vehicle siRNA/miRNA target
RNA gp120 siRNA None tat/rev
RNA CTLA4 siRNA None STAT3
DNA Nucleolin siRNA PEGylated Liposome BRAF
DNA Nucleolin anti miR-21 and
Doxorubicin
Mesoporous silica coated
quantum dots (MSQD)
miR-21
DNA CD4 siRNA None HIV1 protease
DNA MUC1 let-7i miRNA None Cyclin D1, cyclin D2,
Dicer1, PGRMC1
RNA PSMA miR-15a & miR-16-1 PAMAM-PEG Bcl-2, Cyclin D1, Wnt3a
RNA gp120 siRNA None tat/rev
b. Nanoparticle conjugated aptamers
Aptamer type Aptamer target Cargo Vehicle -
RNA CD30 Doxorubicin Gold nanosphere (AuNS) -
DNA PTK7 Doxorubicin Calcium carbonate nanostructure
(CCN)
-
DNA Nucleolin Doxorubicin UCNP-MOF nanocomposites -
DNA PTK7 Doxorubicin Nanoparticle (Gold)/Nanorod
(Gold-Silver)
assembly
-
DNA HER2 Doxorubicin Mesporous silica-carbon
nanoparticles
-
RNA EpCAM Nutlin-3a PLGA nanoparticle -
DNA EpCAM Doxorubicin CMC-MNPs (Carboxymethyl
cellulose-modified
magnetic nanoparticles)
-
RNA EpCAM Doxorubicin PEG-PLGA nanopolymersom-es -
DNA Nucleolin Doxorubicin Au NP -
DNA MUC1 SN38 Chitosan NP -
DNA PTK7 Doxorubicin Gold coated Fe3O4 nanoroses -
RNA EpCAM Curcumin PLGA-Lecithin-PEG NPs -
DNA Nucleolin Doxorubicin pPEGMA-PCL-pPEGMA -
DNA Nucleolin Doxorubicin Single walled carbon nanotubes -
DNA Mucin-1 Epirubicin Super paramagnetic iron oxide
nanoparticles (SPION)
-
RNA PSMA Doxorubicin Super paramagnetic iron oxide
nanoparticles (SPION)
-
c. Micelles/liposome conjugated aptamers
Aptamer type Aptamer target Cargo Vehicle -
DNA Nucleolin Doxorubicin Composite micelle (Pluronic
F127 and beta-CD-PELA)
-
RNA CD44 None PEGylated liposome -
DNA Nucleolin Doxorubicin Liposome -
RNA PSMA Doxorubicin H40-PLA-PEG micelle -
d. Drug only conjugated aptamers
Aptamer type Aptamer target Cargo Vehicle -
DNA Unknown Doxorubicin None -
RNA EGFR Gemcitabine None -
DNA HER2 Doxorubicin None -
DNA Unknown Doxorubicin None -
DNA MUC1 Doxorubicin None -
RNA EpCAM Doxorubicin None -
e. Antibody conjugated aptamer
Aptamer type Aptamer target Cargo Vehicle -
DNA HER2 Doxorubicin Anti-HER2 Ab -
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a. siRNA and other oligonucleotide conjugated aptamers
Aptamer type Study type Model Disease Reference
RNA In vitro CEM, PBMC HIV-1 Zhou et al. 2011
RNA In vitro/ In vivo CD4+, CD8+ T cells/ Mouse Cancer Herrmann et al. 2014
DNA In vitro/ In vivo A375 cells/ Mouse Melanoma Li et al. 2014b
DNA In vitro HeLa Cancer Zhang et al. 2014b
DNA In vitro CD4+ T cells HIV-1 Zhu et al. 2012b
DNA In vitro OVCAR-3 Ovarian cancer Liu et al. 2012a
RNA In vitro LNCaP Prostate cancer Wu et al. 2011
RNA In vivo Humanized mice Rag2−/−γc−/− HIV-1 Neff et al. 2011
b. Nanoparticle conjugated aptamers
Aptamer type Study type Model Disease Reference
RNA In vitro HDLM2, KMH2, L-428, L-540,
SUDHL-1, Kapas 299
Cancer Zhao et al. 2013
DNA In vitro CEM Cancer Zhou et al. 2015
DNA In vitro MCF-7 Cancer Deng et al. 2015
DNA In vitro CEM Cancer Qiu et al. 2015
DNA In vitro/ In vivo SK-BR-3 cells/ Mouse Breast cancer Wang et al. 2015
RNA In vitro MCF7, SKOVK3 & ZR751 Cancer Das et al. 2015
DNA In vitro HepG2 Hepatocellular carcinoma Pilapong et al. 2014
RNA In vitro MCF-7 Cancer Alibolandi et al. 2015
DNA In vitro HeLa, MCF-7 Cancer Shiao et al. 2014
DNA In vitro HT29 Colon cancer Sayari et al. 2014
DNA In vitro CEM Cancer Li et al. 2014a
RNA In vitro HT29 Colon cancer Li et al. 2014c
DNA In vitro MCF-7, PANC-1 Cancer Lale et al. 2014
DNA In vitro/ In vivo PC3 cells/ Mouse Cancer Zhang et al. 2014a
DNA In vitro/ In vivo C26 cells/Mouse Colon cancer Jalalian et al. 2013
RNA In vitro/ In vivo LNCaP cells/ Mouse Prostate cancer Yu et al. 2011
c. Micelles/liposome conjugated aptamers
Aptamer type Study type Model Disease Reference
DNA In vitro/ In vivo MCF-7 cells/ Mouse Cancer Li et al. 2015b
RNA In vitro A549, MDA-MB-231 Cancer Alshaer et al. 2015
DNA In vitro/ In vivo MCF-7 cells/ Mouse Cancer Xing et al. 2013b
RNA In vitro/ In vivo CWR22Rν1 cells/ Mouse Prostate cancer Xu et al. 2013a
d. Drug only conjugated aptamers
Aptamer type Study type Model Disease Reference
DNA In vitro HCT116 Cancer Li et al. 2014d
RNA In vitro MiaPaCa-2 Pancreatic cancer Ray et al. 2012
DNA In vitro SK-BR-3 Breast cancer Liu et al. 2012b
DNA In vitro/ In vivo LH86 cells/ Mouse Liver cancer Meng et al. 2012
DNA In vitro A549 Cancer Hu et al. 2012
RNA In vitro Y79, WERI-Rb1 Retinoblastoma Subramanian et al. 2012
e. Antibody conjugated aptamer
Aptamer type Study type Model Disease Reference
DNA In vitro SK-BR-3 Cancer Kang and Hah 2014
Table 2. (continued)
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In another work, CD44 specific RNA aptamer, Apt1, was
bound to PEGylated liposomes using the thiol-maleimide
click reaction. It was observed that the binding affinity of
Apt1–liposome conjugate increased as compared to the free
Apt1 to CD44, and also, Apt1-liposome had higher sensitiv-
ity and selectivity compared to the blank liposomes. In
conclusion, anti-CD44 aptamer liposome conjugate (Apt1-
lip) could be used as a potential system for specific drug
delivery in cancer cells (Alshaer et al. 2015).
The majority of work in aptamer functionalized liposome
drug delivery has been done in vitro. However, a recent work
has confirmed the efficient role of liposomes in in vivo as
well. In this study, AS1411 aptamer functionalized lipo-
somes carrying doxorubicin payload increased cellular inter-
nalization and cytotoxicity to MCF-7 breast cancer cells as
compared to non-functionalized liposomes. Also, in the xe-
nograft MCF-7 breast tumors in athymic nude mice, the
aptamer functionalized liposomes showed enhanced tumor
penetration and cytotoxicity (Xing et al. 2013a). Similar
work, where aptamer functionalized liposomes or micelles
were used for specific drug delivery in vivo has been per-
formed by others as well (Baek et al. 2014).
3.4 Aptamer–drug conjugates
There are several anthracycline based drugs, viz., doxorubi-
cin, daunorubicin and epirubicin that are currently being
used for the treatment of cancer. However, a side effect
caused by the off-target binding of these drugs is a cause
of major concern. To overcome this problem aptamer-drug
conjugates have been developed recently using covalent or
non-covalent interactions. Compared to the drug alone these
aptamer-drug conjugates are easy to make and have signif-
icantly higher specificity and cytotoxicity enabling localized
targeting of the drug. Dox causes cytotoxicity by its ability to
intercalate between the GC or CG base pairs in the DNA.
The same concept is used to bind Dox to the oligonucleotide
aptamers, and then its delivery in the cells.
In spite of the advantages of the apt-drug conjugates,
there are limitations. However, work is in progress to alle-
viate these limitations. First, the weakly stable noncovalent
aptamer-drug conjugates can be stabilized by using covalent
interaction, where, the drug is bound covalently to the
aptamer through a functional linker moiety. Secondly, the
short half-life of aptamer-drug conjugates in vivo may be
enhanced by the addition of PEG to the aptamer. In addition,
the PEGylation of the aptamer also enhances their stability
and reduces their toxic accumulation in non-target tissues
(Taghdisi et al. 2013; Tan et al. 2011). Lastly, aptamers are
known to have a very poor drug payload capacity because of
its very simple structure, which can be overcome to some
extent by synthesizing polyvalent aptamers (Zhang et al.
2013).
Using aptamers alone along with cancer drugs directly
may help in reducing off-target effects of anti-cancer drugs
and increase their potency. For this purpose a conjugate of
modified aptamer TLS11a-GC with an antitumor drug doxo-
rubicin was prepared which displayed both high potency and
target specificity to liver cancer cells. Here, the non-specific
uptake of membrane permeable drug Dox was prevented by
its conjugation with the target specific aptamer (Meng et al.
2012).
In a similar example, a conjugate of RNA aptamer against
EpCAM with Doxorubicin was used to deliver the chemo-
therapeutic drug to the retinoblastoma cells thereby prevent-
ing their proliferation (Subramanian et al. 2012). EpCAM,
used in this study, is overexpressed in most of the solid
cancers and is a cancer stem cell (CSC) marker (Shigdar
et al. 2011). In this study, EpCAM aptamer (EpDT3-apt)
conjugated with doxorubicin was able to bind specifically
and internalize the nucleus of retinoblastoma cell lines Y-71
and WERI-Rb1 but not to the control Muller glial cells. The
presence of EpCAM in various cancers also allows the
EpCAM aptamer-Dox conjugate to be used as a therapeutic
agent against all the cancers overexpressing EpCAM, viz.,
breast cancer, pancreatic cancer, colorectal cancer and liver
cancer.
CD44 belongs to proteoglycan family of transmembrane
glycoproteins and a primary receptor for hyaluronic acid
which in turn plays an important role in tumor growth and
metastasis. The hyaluronic acid binding domain (HABD) is
conserved among the CD44 splicing variants. Hence, Soma-
sunderam et al. (2010) specifically selected thioaptamer
binding to the CD44’s HABD with 180–295 nM affinities.
These thioaptamers specifically bound to CD44 positive
human ovarian cancer cell lines when compared with the
CD44 negative NIH3T3 cell line. The selected thioaptamers
can further be developed as a targeting or imaging agent for
the delivery of therapeutic payloads for cancer tissues
(Somasunderam et al. 2010).
3.5 Aptamer–antibody conjugate
It is known that a dimer of antibodies that recognize adjacent
and non-overlapping epitopes of the same target antigen
have enhanced receptor binding (Kang and Hah 2014). This
increase in affinity occurs due to the increase in kon value
and decrease in koff value, which ultimately leads to the
increase in dissociation constant (Kd) value for the dimer as
compared to either of the two antibodies alone. In the past
both antibody homodimer, and aptamer homodimer and
heterodimer have been made (Kang and Hah 2014). How-
ever, in an attempt to increase the affinities of antibodies or
aptamers to their target molecule, the antibody-aptamer pin-
cer or heterodimer was made.
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Since aptamers are advantageous over antibodies due to
their high binding affinity and the ability to undergo numer-
ous chemical modifications they can be used instead of
antibodies to form aptamer-antibody dimers. Kang and Hah
(2014) worked in this direction and called these dimers as
antibody-aptamer pincers (AAP). AAP has a higher affinity
with sustained or possibly higher specificity for its target
molecule. The group also observed drug delivery along with
higher cytotoxicity in cancer cells. To use AAP as a platform
for therapeutic delivery the anti-HER2 aptamer and anti-
HER2 monoclonal antibody conjugate was loaded with
doxorubicin, and the resulting AAP-HER2-Dox conjugate
showed an approximately 3- and 6- fold higher cytotoxicity
than drug alone and antibody alone, respectively (Kang and
Hah. 2014). Thus, the conjugation of the aptamer and the
antibody can significantly improve the affinities of the
resulting AAPs towards their target molecules and the drug
loaded AAP may be used as a platform for targeted drug
delivery against many malignancies.
4. Aptamers in imaging
Traditional imaging techniques primarily rely on morpho-
logical evidence, to example X-rays in CAT scans, radio-
labeled compounds (e.g. fluorodeoxyglucose) in PET, MRI,
and sonography. These techniques are used routinely in the
clinic, for example in cancer detection strategies.
Alternatively, molecular imaging uses specific molecular
probes to discriminate specific biological events (Massoud
et al. 2003). The advances of molecular imaging are: (i) the
ability to detect diseases at an earlier stage, (ii) measure and
characterize its pathogenesis, and (iii) use them in in vitro and
in vivo assays. By using specific molecular probes particular
biological processes or targets can be visualized (Wang and
Farokhzad 2014). Aptamers are a very interesting class of
molecular probes due to their ability to spontaneously fold into
3D scaffolds with similar binding recognition as antibodies.
The great advantages of aptamers over antibodies are due to
stability and relative ease of chemical modification. Another
advantage is that they can be produced synthetically. Their
smaller size than antibodies gives them the added advantages
of higher tissue penetration and increased systemic clearance.
These advantages are beneficial for diagnostics as well (Cruz-
Aguado and Penner 2008).
We will highlight a few examples of molecular probes for
traditional clinical imaging purposes and then briefly discuss
general conjugation strategies applicable for RNA and DNA
aptamers intended for imaging.
4.1 MR imaging
Traditional gadolinium-based magnetic resonance (MR)
contrast agents are mostly used to provide non-invasive
two- and three-dimensional images of living specimens.
Recently the need for smart contrast agents that induce
detectable MRI responses in the presence of specific targets
are under investigation (Lauffer 1987; Caravan et al. 1999).
Since the first responsive Ca2+-chelator for gadolinium, that
induced changes in the longitudinal relaxation time of water
protons (referred to as T1) by Meade et al. (Li et al. 2002),
only a few other systems have been reported (Xu and Lu.
2011). SPIONs have advantages over tradit ional
gadolinium-based MR contrast agents due to their lower
toxicity, stronger enhancement of proton relaxation, and
lower detection limit. However, they are still less widely
used clinically than gadolinium compounds.
Both SPIONs and responsive chelator systems for gado-
linium have been combined with aptamer technology. The
A10 RNA aptamer (Farokhzad et al. 2004) was conjugated
to a TLC-SPION using standard coupling chemistry (Wang
et al. 2008). The complex was aimed to target PSMA in
prostate cancer lymph node disease. In addition, the
aptamer-TLC-SPION-MR contrast agent was loaded with
doxorubicin for targeted delivery. An example of a respon-
sive system by Xu and Lu (2011) was via a NHS coupled
DNA aptamer against adenosine and to gadolinium-
tetraazacyclododecane tetraacetic acid (DOTA-Gd). The
MRI agent increased the T1 responds on binding of the
aptamer to its target, thus reducing the intensity of the signal
upon binding. In a follow-up study the authors demonstrated
an opposite effect and increase in MRI signal upon binding
with uranyl cations via a 39E DNAzyme-based smart MRI
contrast agent (Xu et al. 2013b).
4.2 CT imaging
The A10 aptamer, targeted against PSMA (Farokhzad et al.
2004), was conjugated to gold nanoparticles (Kim et al.
2010). A thiol-modified capture probe (5′-HS-CC-(A)10-
TCGTCGTCGTCGTCGTCGTCG-3′) was covalently
bound to 13 nm gold particles. The A10 aptamer was then
hybridized to the capture probe. Due to the high atomic
number, gold nanoparticles can act as CT imaging contrast
agents (Kim et al. 2007; Popovtzer et al. 2008).
Kim et al. (2010) demonstrated that the A10 aptamer-
nanoparticles bind specifically to PSMA-expressing prostate
cancer cells and the feasibility of these particles to be used as
molecular probes for the detection of PSMA-expressing
cancer cells by CT imaging. In another recent example,
Kuo et al. (2014) conjugated the AS1411 aptamer to
europium-doped gadolinium oxide nanoparticles to target
nucleolin, which is highly expressed in CL1-5 lung cancer
cells. Due to their florescent nature, these particles can be
used as a visual marker, but also act as contrast agents in MR
and CT due their excellent T1 contrast and strong CT signal.
Aptamers in diagnostics, drug-delivery and imaging 553
J. Biosci. 41(3), September 2016
4.3 Ultrasound imaging
Ultrasound is a commonly used clinical imaging technique.
Advances to overcome the low resolution have resulted in
the use of micro- and nano-bubbles to increase the contrast
(Gramiak and Shah 1968; Ferrara et al. 2007). In addition,
this technique has been utilized in sonodynamic therapy,
ultrasound-mediated chemotherapy, ultrasound-mediated
gene delivery and anti-vascular ultrasound therapy (Wood
and Sehgal 2015). Specific biomarkers have been targeted
via antibodies or small peptides (Chen et al. 2015; Huang
et al. 2015), and recently aptamers (Wang et al. 2011b).
In order to overcome immunogenic side effects due to biotin-
avidin conjugations an easier method for functionalize bubbles
was developed byWang et al. (2011b). Disulfide sgc8c aptamer
was conjugated to PEG-maleimide in a lipid mixture of 1,2-
Distearoyl-sn-glycero-3-phosphocholine DSPC (95%),
PEG2000-1,2-Distearoyl-sn-glycero-3-phosphoethanolamine
(DSPE; 2.5%), and the maleimide-functionalized PEG-DSPE.
Nano-bubbles were generated by mechanical activation and the
whole formulation took 2 hours. The sgc8c aptamer was linked
to an imaging agent for the specific targeting of T-cell, human
acute lymphoblastic leukemia (CCRF-CEM cells). Due to the
strong binding of the aptamer to CEM cells and excellent
hydrodynamic stability, the nanoparticles also exhibited superi-
or behavior in local accumulation under flow conditions. Micro-
bubbles can also act as a stimulus-responsive contrast agent. For
the detection of thrombosis, or malignant blood clot formation,
and in vivo clot activity Nakatsuka et al. (2012) developed
aptamer-thrombin and polymer-DNA coated microbubbles
where the aptamer can bind to thrombin and the DNA of the
polymer-DNA coating. Microbubble shell components were
prepared so that they would respond to thrombin. Poly(acrylic
acid) (PAA) was coupled to the amine of DSPE via
carbodiimide-mediated amidation. Subsequently two amine ter-
minated DNA strands were attached. A DNA strand, the throm-
bin aptamer crosslinking strand (TACS) contained a portion
complementary to the polymer-DNA to induce crosslinking,
as well as two flanking 15-base DNA aptamer sequences. Both
strands each possessed a half maximal inhibitory concentration
(IC50) in the order of 25 nM for thrombin. Nine of the fifteen
aptamer bases are left unbound at the ends of the crosslinking
strand so that the binding of thrombin resulted in the complete
displacement of the TACS from the polymer-DNA strands.
Therefore, upon binding to thrombin the aptamer was displaced
from the complex to generate an ultrasound signal. No signal
was observed in normal blood conditions.
4.4 Nuclear imaging
Radionuclide-based imaging techniques, such as SPECT and
PET, have excellent tissue penetration capability. Especially,
pre-targeting and immunotargeting of drug carriers in
combination of SPECT/CT have great potential (Lehtinen
et al. 2012). Several radioisotopes are in use, such as 99mTc,
111In, and 125I for SPECT, 11C, 18F, 76Br, and 64Cu for PET
(Younes et al. 2002; Perkins and Missailidis. 2007; Lucignani
2006). A radiolabeled aptamer (NX21909-99mTc) against neu-
trophil elastase to identify inflammation was the first report of
such an imaging probe (Charlton et al. 1997). Here the authors
conjugated a peptide-N3S1-type Tc-binding via the amine
linker of the NX21909 aptamer by NHS-ester reaction in dry
DMSO/5% triethylamine. Compared to IgG probes the target-
to-background ratio was increased 4-fold due to more rapid
clearance of unbound aptamers.
Also, in the case of a radiolabeled aptamer against the
extracellular matrix protein tenascin-C the rapid clearance
from the blood-stream gave a 50:1 tumor to blood ratio. The
TTA1 aptamer was developed in a SELEX against tumor cells
and purified tenascin-C, after initial discovery of an aptamer to
U251 glioblastoma cells (Daniels et al. 2003; Hicke et al.
2001). TTA1 aptamer was bioconjugated with technetium
chelator MAG2-uccinimidyl ester (Hilger et al. 1999) through
the 5′ amine in dimethylformamide (Winnard et al. 2008).
MAG2 was either labeled with
99mTc, 111In or 32P.
Other examples are 99mTc-labeled aptamer against MUC1
protein (a tumor biomarker) (Da Pieve et al. 2009), the
AS1411 aptamer targeted against nucleolin (a cobalt-ferrite
nanoparticle) labeled with 67Ga (Hwang et al. 2010), and the
aptamer HYNIC against tyrosine kinase-7 labeled with
99mTc to image acute lymphoblastic leukemia CCRF-CEM
cells (Calzada et al. 2014).
4.5 Fluorescence imaging
Fluorophores can be labeled to the 5′- or 3′-prime end or in the
middle of aptamers by use of phosphoramidite chemistry. Fluo-
rescence of this nature has been widely applied in cancer imag-
ing (Wu et al. 2015). Fluorescently tagged RNA aptamer has
been applied in the detection of amyloid plaques in both ex vivo
human Alzheimer’s disease brain tissue and in vivo APP/PS1
transgenic mice. Imaging probes were introduced in the anti-Aβ
RNA aptamer, β55, by transcription of the DNA template with
T7 RNA polymerase by either using biotin-labeled uracil, for
ex vivo studies, or fluorescein-labeled uracil directly.
Alternatively, displacement of a fluorescently labeled
oligo from the aptamer by the target can be detected by
fluorescence polarization (FP/FA) (Cruz-Aguado and Penner
2008). Here, a small ssDNA aptamer of 36 bases bound
specifically to the small molecule ochratoxin A and levels
as low as 5 nM could be detected with the FP displacement
assay. Fluorescence polarization or anisotropy analysis has
also been applied to map aptamer-protein interactions.
Zhang et al. (2011) studied human α-thrombin and aptamer
TA29 to identify 3 thymines and the 3’-end of the aptamer as
the closest contact groups.
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4.6 Labelling, conjugation and ligation
Due to their synthetic nature, chemical modification of aptamers
is relatively easy. For therapeutic purposes a durable perfor-
mance of aptamers in vivo and prolonged half-lives are required
(Wang et al. 2011a, b). For imaging purposes, most aptamers are
conjugated or hybridized to DNA/RNA with imaging moieties.
Typically, the architecture of the bioconjugate has to be adjusted
to the application for which it is developed (Canalle et al. 2010).
In a recent review by Paredes et al. (2011) strategies are
discussed in great detail for RNA labelling, conjugation and
ligation. Summarizing, imaging labels or the introduction of
moieties for later labelling can be introduced via internal
handles. In addition, synthetic chemistry, enzymatic incorpo-
ration and labelling or conjugation chemistry can be applied to
modify RNA. Many strategies presented can be applied to
DNA as well. Incorporation of labels via solid-phase RNA
synthesis has been applied for incorporation of 32P (Hilger
et al. 1999; Paredes et al. 2011; Winnard et al. 2008) and by
use of phosphoramidites for the synthesis of RNA with mod-
ifications at the 5′-end (Paredes et al. 2011). In post-synthetic
labelling and conjugation, four general chemical strategies
based on reactive species can be identified, viz. periodate
chemistry (Paredes et al. 2011), amine chemistry, thiol chem-
istry, and click chemistry (Canalle et al. 2010; Paredes et al.
2011). In enzymatic incorporation of labels and reactive tags
T4 polynucleotide kinase, terminal transferase, DNA polymer-
ase I, T7 RNA polymerase, Poly (A) polymerase, and T4 RNA
ligase have been used (Paredes et al. 2011). In chemical
ligations native phosphate linkage by cyanogen bromide or a
water-soluble carbodiimide and the subsequent reaction with a
hydroxyl group has been utilized (Paredes et al. 2011). DNA
splits and peptides have been used via these methods. Both
protein and nucleic acid enzymes can be used to ligate two
strands of RNA, or DNA. Most commonly used is T4 DNA
ligase. Alternatively, T4 RNA ligase 1, T4 RNA ligase 2, and
deoxyribozymes (DNAzyme) have been used for ligation and
fluorescent labelling of RNA (Paredes et al. 2011).
5. Conclusion
Various aptamers have been selected to detect a wide range of
targets; however, a significant number of them have not been
used for diagnostic applications. These aptamers need further
development to be used in biosensors to increase the efficiency
and their ability to detect targets in clinical samples. Mostly the
problem lies in clinical sample preparation, which is tedious,
time consuming, costly and needs expertise. So aptamers must
be tuned to detect the antigen at low concentration and in
presence of serum impurities. Biosensors involving aptamers
should have high range of sensitivity concerning the signal
amplification. Some aptamers need to be more specific to-
wards their target, mostly in case of cancer detection in vivo,
where they have shown nonspecific signals when tested in
mice. Aptamers have already proven to be a better candidate
for target binding than its other counterparts and, hence, will
maintain its position in diagnosis. To do so, the developed
biosensors or diagnostic tests involving aptamers should be
tested with human samples and should be taken from research
labs to diagnostic labs. In case of drug delivery, aptamers have
emerged as a new set of biomolecules that are efficient in
highly specific delivery of a payload to the target cells both
in vitro and in vivo. Their sturdiness and ability to undergo a
range of chemical modifications gives an advantage of binding
aptamers with various payloads. Also, aptamer binding and
delivery to the cells can be increased by conjugation with
nanoparticles, liposomes and even antibodies. Until now, an
overwhelming majority of the work for targeted delivery using
aptamers has been done in cancer with a very limited number
of attempts on other diseases like HIV, AMD and few others.
This leaves a wide possibility of using aptamers for targeted
delivery of drugs in a myriad range of diseases as well. Also, a
push has to be given towards taking the studies from in vitro to
in vivo and clinical level, as relatively large amount of work, at
present, is limited to the targeted delivery of aptamers at
in vitro level only. Coming towards imaging applications,
aptamers due to their small size, specific binding, and stability
have great potential for clinical and molecular imaging. Their
stability and self-assembly after heating makes them superior
over protein-based binding molecules, such as antibodies
(Daugherty and Mrsny 2006) or even affibodies (Feldwisch
2010) in terms of labelling and conjugation strategies.
We expect that in the near future more combinations of
diagnostics, drug-delivery and imaging aptamer based tools
to be combined into integrated methods to detect, visualize
and treat (infectious) diseases in vivo at the same time.
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